Analyse Traws Pharma, Inc. (TRAW) — Kairos Score 41/100

À propos de Traws Pharma, Inc.

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Informations clés

🕴️ Activité des initiés (90 jours)

0 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Traws Pharma, Inc..

🏦 Hedge Funds

3 fonds institutionnels déclarent une position sur TRAW dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur TRAW.

• Traws Pharma shares rise after Q2 loss comes in better than expected
• Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.